- Home
- ABLV vs DXR Comparison
ABLV vs DXR Comparison
Compare ABLV & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABLV | DXR |
|---|---|---|
| Founded | 2015 | 1970 |
| Country | China | United States |
| Employees | 89 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 71.4M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | ABLV | DXR |
|---|---|---|
| Price | $0.65 | $10.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.2K | ★ 11.9K |
| Earning Date | 04-23-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ $16.70 | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.59 | $7.10 |
| 52 Week High | $1.77 | $14.76 |
Technical Indicators
Market Signals| Indicator | ABLV | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 30.55 |
| Support Level | $0.60 | $10.00 |
| Resistance Level | $0.73 | $10.49 |
| Average True Range (ATR) | 0.03 | 0.40 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 31.25 | 18.56 |
Price Performance
Historical ComparisonAbout ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.